[ad_1]
Coronavirus: News from China is encouraging, as a candidate coronavirus vaccine has shown 86% effectiveness, based on the results of a phase 3 trial in the United Arab Emirates.
The vaccine has already been tested in about 1 million people in China and the company promoting it is the state pharmaceutical company Sinopharm.
The vaccine efficacy rate may be lower than the Western approved vaccines from Pfizer / BioNTech, Moderna, and AstraZenecca, but is well above the minimum acceptable rate of 50%. It is worth noting that the Sinopharm vaccine has the advantage that it can be stored cold and does not require deep freezing like other vaccines.
As pointed out Wall street journal, “This makes the Sinopharm vaccine a potential candidate for many countries, especially in emerging markets that do not have immediate access to vaccines from the West. The vaccine can be stored at normal refrigerator temperatures, unlike BioNTech / Pfizer vaccines. and Modern. “This makes it an attractive option for developing countries that do not have an advanced supply refrigeration infrastructure.”
Phase 3 testing of the Sinopharm vaccine has been done since July. Approximately 31,000 volunteers participated in the trials, which tested two versions of the vaccine: one developed in a laboratory in Beijing and another developed in a laboratory in Wuhan.
the United Arab Emirates had previously announced that 1/3 of the participants took the placebo, while two-thirds took the Beijing version. However, the exact number of participants is unknown. It should be noted that the UAE has registered this vaccine for emergency use since September.
According to the announcement by the company and the United Arab Emirates, a percentage of those who made the vaccine were infected, however the vaccine was 100% effective in preventing moderate and severe cases of the disease. The analysis also showed that 99% of the participants developed antibodies against the disease, according to the statement.
the Sinopharm vaccine candidate, or China National Pharmaceuticals Group, is based on a inactivated virus, which means the pathogen is attenuated for use in humans.
“The Sinopharm results are in contrast to another Chinese Covid-19 vaccine, the CoronaVac candidate from Sinovac Biotech Ltd., which showed vague results in early tests on its level of protection.” it is noted.
News from Greece and the world, as it happens, on Newsbomb.gr.
Read also:
Crash in Vrilissia: cold execution day – midday in the middle of the road
